공시 • Mar 19
Dispensa Group Announces Cancellation of Trading of Ordinary Shares on the Main Market for Listed Securities of the London Stock Exchange Further to the announcements made on 16 February and 14 March 2024, Dispensa Group Plc announced that the listing of the company's Ordinary Shares on the Official List of the Financial Conduct Authority and admission to trading on the Main Market for listed securities of the London Stock Exchange plc have now been cancelled with effect from 8.00 a.m. (London time) 19 March 2024. 공시 • Feb 17
Dispensa Group Plc, Annual General Meeting, Mar 14, 2024 Dispensa Group Plc, Annual General Meeting, Mar 14, 2024, at 11:00 Coordinated Universal Time. Location: 50 Sloane Avenue, London SW3 3DD SW3 3DD London United Kingdom 공시 • Feb 14
Dispensa Intends to Delist its Ordinary Shares from the U.K.'s Financial Conduct Authority's Official List, and Cancel its Listing on the London Stock Exchange Dispensa Group Plc said it intends to delist its ordinary shares from the U.K.'s Financial Conduct Authority's official list, and cancel its listing on the London Stock Exchange. The e-commerce and retail technology company--formerly known as Zamaz--said the decision aims to maximize shareholder value and increase the company's potential for long-term success. The board said the challenges behind the implementation of its growth-acquisition strategy in a listed environment, the considerable management time and cost of remaining listed at this stage of the company's development, as well as current market conditions, were key factors behind the decision. The company also said that its strategy of buying undervalued, traditional premium brand businesses and digitizing their systems and processes to increase revenue, margins and value, is more suited to a private equity environment focusing "on longer-term initiatives, without the shorter-term reporting timelines of public equity markets." Dispensa said it will send out a circular setting out further details of the delisting, and its implications, by February 16. "The company also notes that the delisting would enable it to make numerous cost savings to the benefit of Shareholders and that it will implement a cost efficiency program should the delisting be approved," it said. New Risk • Feb 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €7.92m (US$8.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (€7.92m market cap, or US$8.53m). Minor Risk Latest financial reports are more than 6 months old (reported February 2023 fiscal period end). New Risk • Jan 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported February 2023 fiscal period end). Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (€18.6m market cap, or US$20.2m). Buying Opportunity • Dec 16
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be €0.046, however this is not to be taken as a buy recommendation but rather should be used as a guide only. 공시 • Nov 23
Dispensa Group Plc Announces Chief Executive Officer Changes Dispensa Group Plc announced that Mr. Alessandro Colombo is stepping down from his role as Chief Executive Officer for pressing personal reasons and has agreed with the Company that he will leave with immediate effect. Mr. Daniele Besnati has been re-appointed Interim Chief Executive Officer, a role he held immediately prior to Mr. Colombo's appointment. A further announcement regarding a new permanent appointment will be made in due course. Board Change • Oct 31
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman Niccolo Caderni was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Oct 20
Dispensa Group plc Appoints Alessandro Colombo as CEO with Immediate Effect Dispensa Group plc announced the appointment of Mr. Alessandro Colombo as CEO with immediate effect. Mr. Colombo, 56, is a highly experienced executive who has held senior leadership positions within both public and private companies as General Manager and CEO. Most recently, Mr. Colombo was the Area General Manager for Italy at Sonder, a leading hospitality group, where he was responsible for strategy and operations as well as delivering record revenue growth. Prior to this, Mr. Colombo was Chief Executive Officer at IKB Corporate Lab, a joint-venture between UniCredit and IKB in the financial sector, and a Vice President in investment banking at Credit Suisse First Boston, where he advised corporate clients on corporate strategy, M&A and fundraisings. Mr. Colombo has also worked as a corporate finance manager at Swiss insurance company, Assura S.A. and as a management consultant for McKinsey & Co. An Italian national, Mr. Colombo speaks five languages, and has experience of working across mainland Europe and in the UK. He holds a degree in Economics from Bocconi and an MBA from the University of California, Los Angeles. Mr. Colombo's current and past directorships are as follows: Past five years: Sonder Italy S.r.l., special attorney (legal representative) from December 10, 2018 until June 30, 2023 Director from October 28, 2019 until November 21, 2019. 공시 • Aug 24
Zamaz plc Announces Board Changes Zamaz plc announced that Dr Niccolò Caderni, previously a Non-Executive Director of the Company, has been appointed Non-Executive Chairman with immediate effect. The previous Chairman, Martin Groak has moved to a Non-Executive Director role and remains as chairman of the Audit Committee.